Testing effectiveness (Phase 2)Active Not RecruitingNCT04079712
What this trial is testing
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
Who this might be right for
Metastatic Large Cell Neuroendocrine CarcinomaMetastatic Neuroendocrine CarcinomaMetastatic Neuroendocrine Neoplasm+1 more
National Cancer Institute (NCI) 17